New hope for kids with resistant cancers: targeted drug enters trial
NCT ID NCT07630974
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called ifinatamab deruxtecan (I-DXd) in children with solid tumors that have returned or not responded to treatment. The drug is an antibody-drug conjugate that targets cancer cells directly. The trial aims to check safety and see if tumors shrink in about 134 children with specific cancer types.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ifinatamab deruxtecan (I-DXd)
What this could lead to
If it works, this could offer a new treatment option for children with hard-to-treat solid tumors that have come back or not responded to standard therapy.
What could go wrong
This is an early-phase trial with a small number of children, so results may not apply to all patients. The drug may cause side effects or not shrink tumors as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WILMS TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.